DE3710216A1 - Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen - Google Patents
Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungenInfo
- Publication number
- DE3710216A1 DE3710216A1 DE19873710216 DE3710216A DE3710216A1 DE 3710216 A1 DE3710216 A1 DE 3710216A1 DE 19873710216 DE19873710216 DE 19873710216 DE 3710216 A DE3710216 A DE 3710216A DE 3710216 A1 DE3710216 A1 DE 3710216A1
- Authority
- DE
- Germany
- Prior art keywords
- dihydroergotamine
- salts
- treatment
- dosage forms
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 title claims abstract description 23
- 229960004704 dihydroergotamine Drugs 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- 208000014306 Trophic disease Diseases 0.000 title claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 208000017520 skin disease Diseases 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 206010040943 Skin Ulcer Diseases 0.000 claims description 6
- 239000008297 liquid dosage form Substances 0.000 claims description 5
- 239000008299 semisolid dosage form Substances 0.000 claims description 5
- 208000005230 Leg Ulcer Diseases 0.000 claims description 4
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000007909 solid dosage form Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract description 2
- 208000025865 Ulcer Diseases 0.000 description 14
- 231100000397 ulcer Toxicity 0.000 description 12
- 239000002552 dosage form Substances 0.000 description 9
- 206010052428 Wound Diseases 0.000 description 8
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 206010048768 Dermatosis Diseases 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000002816 chronic venous insufficiency Diseases 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 201000002282 venous insufficiency Diseases 0.000 description 2
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000004056 Orthostatic intolerance Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 206010048629 Wound secretion Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000013039 cover film Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 235000019381 petroleum wax Nutrition 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- KOODSCBKXPPKHE-UHFFFAOYSA-N propanethioic s-acid Chemical compound CCC(S)=O KOODSCBKXPPKHE-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000019432 tissue death Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873710216 DE3710216A1 (de) | 1987-03-27 | 1987-03-27 | Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen |
| JP63044662A JP2593906B2 (ja) | 1987-03-27 | 1988-02-29 | 栄養性障害の局所治療に用いるジヒドロエルゴタミン及び／又はその塩を含有する薬剤とその製造方法 |
| EP88103929A EP0285856B1 (de) | 1987-03-27 | 1988-03-11 | Verwendung von Dihydroergotamin und seinen Salzen zur lokalen Behandlung trophischer Störungen |
| DE8888103929T DE3881257D1 (de) | 1987-03-27 | 1988-03-11 | Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen. |
| AT88103929T ATE89728T1 (de) | 1987-03-27 | 1988-03-11 | Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen. |
| US07/171,545 US4916132A (en) | 1987-03-27 | 1988-03-22 | Use of dihydroergotamine and its salts for the local treatment of trophic disturbances |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873710216 DE3710216A1 (de) | 1987-03-27 | 1987-03-27 | Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3710216A1 true DE3710216A1 (de) | 1988-10-06 |
| DE3710216C2 DE3710216C2 (enExample) | 1991-02-28 |
Family
ID=6324182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19873710216 Granted DE3710216A1 (de) | 1987-03-27 | 1987-03-27 | Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen |
| DE8888103929T Expired - Fee Related DE3881257D1 (de) | 1987-03-27 | 1988-03-11 | Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8888103929T Expired - Fee Related DE3881257D1 (de) | 1987-03-27 | 1988-03-11 | Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen. |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4916132A (enExample) |
| EP (1) | EP0285856B1 (enExample) |
| JP (1) | JP2593906B2 (enExample) |
| AT (1) | ATE89728T1 (enExample) |
| DE (2) | DE3710216A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2312585T3 (es) * | 2001-06-05 | 2009-03-01 | Ronald Aung-Din | Terapia contra la migraña por via topica. |
| US8329734B2 (en) * | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
| FR2837708B1 (fr) * | 2002-04-02 | 2005-02-04 | Schwarz Pharma Lab | Utilisation de la 8'-hydroxydihydroergotamine pour la fabrication d'un medicament contre la migraine |
| DE10233740A1 (de) * | 2002-07-24 | 2004-02-05 | Basf Ag | Retinoid-haltige Zubereitungen |
| EP1644004A4 (en) * | 2003-06-20 | 2010-10-06 | Ronald Aung-Din | LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS |
| US20070232561A1 (en) * | 2006-03-31 | 2007-10-04 | Edward Leung | Pharmaceutical compositions for promoting wound healing |
| CA2729346A1 (en) | 2008-06-30 | 2010-01-14 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
| WO2014100351A2 (en) | 2012-12-21 | 2014-06-26 | Map Pharmaceuticals, Inc. | 8'-hydroxy-dihydroergotamine compounds and compositions |
| US20140179705A1 (en) * | 2012-12-21 | 2014-06-26 | Map Pharmaceuticals, Inc. | 8'-hydroxy-dihydroergotamine compounds and compositions |
| US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
| EP3265081A4 (en) | 2015-03-02 | 2018-11-21 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoids |
| EP3281649A1 (en) * | 2016-08-09 | 2018-02-14 | Teleflex Lifesciences | Wetting agent formulation |
| US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2528516A1 (de) * | 1974-07-05 | 1976-01-22 | Sandoz Ag | Neue galenische zubereitung |
| DE3333240A1 (de) * | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur transdermalen applikation von arzneimittelwirkstoffen |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1175430A (en) * | 1966-04-07 | 1969-12-23 | Sandoz Ltd | Pharmaceutical Compositions containing Ergot Alkaloids |
| DE2750090A1 (de) * | 1976-11-19 | 1978-06-01 | Sandoz Ag | Neue verabreichungsformen fuer organische verbindungen |
| US4451458A (en) * | 1980-02-07 | 1984-05-29 | Sandoz Ltd. | Method for the treatment of post-operative thrombosis |
| FR2477015A1 (fr) * | 1980-03-03 | 1981-09-04 | Fabre Sa Pierre | Composition pharmaceutique a base d'un alcaloide de l'ergot de seigle, a activite regulatrice sur le tonus vasculaire |
| FR2483235A1 (fr) * | 1980-05-28 | 1981-12-04 | Fabre Sa Pierre | Compositions a usage topique contenant des alcaloides de l'ergot de seigle et de vinca rosea destinees au traitement des hyperseborrhees |
| DE3227122A1 (de) * | 1982-07-20 | 1984-01-26 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Stabile loesungen von mutterkornalkaloiden |
| AT381232B (de) * | 1985-05-13 | 1986-09-10 | Kwizda Fa F Johann | Verfahren zur herstellung stabiler fluessiger loesungen von ergolinderivaten |
-
1987
- 1987-03-27 DE DE19873710216 patent/DE3710216A1/de active Granted
-
1988
- 1988-02-29 JP JP63044662A patent/JP2593906B2/ja not_active Expired - Lifetime
- 1988-03-11 DE DE8888103929T patent/DE3881257D1/de not_active Expired - Fee Related
- 1988-03-11 AT AT88103929T patent/ATE89728T1/de not_active IP Right Cessation
- 1988-03-11 EP EP88103929A patent/EP0285856B1/de not_active Expired - Lifetime
- 1988-03-22 US US07/171,545 patent/US4916132A/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2528516A1 (de) * | 1974-07-05 | 1976-01-22 | Sandoz Ag | Neue galenische zubereitung |
| DE3333240A1 (de) * | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur transdermalen applikation von arzneimittelwirkstoffen |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3881257D1 (de) | 1993-07-01 |
| EP0285856B1 (de) | 1993-05-26 |
| DE3710216C2 (enExample) | 1991-02-28 |
| JP2593906B2 (ja) | 1997-03-26 |
| EP0285856A2 (de) | 1988-10-12 |
| US4916132A (en) | 1990-04-10 |
| ATE89728T1 (de) | 1993-06-15 |
| EP0285856A3 (en) | 1990-12-05 |
| JPS63243027A (ja) | 1988-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69007626T2 (de) | Verwendung von algenextrakten zur herstellung von pharmazeutika, kosmetika, nahrungsmitteln oder zum landwirtschaftlichen gebrauch. | |
| DE3856018T2 (de) | Verwendung von einer Disaccharidpolysulfat-Aluminium Verbindung zur Herstellung eines Medikaments zur Behandlung von HÄMORRHOIDEN und zur Wundheilung | |
| DE69430903T2 (de) | Behandlung von periodontitis mit misoprostol | |
| EP1711190A1 (de) | Mittel zur behandlung von entz ndlichen erkrankungen | |
| DE3710216C2 (enExample) | ||
| DE69027220T2 (de) | Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen | |
| DE60112431T2 (de) | Verwendung von biguanidederivaten zur herstellung eines vernarbungsfördernden medikaments | |
| DE3205504A1 (de) | Aeusserlich anwendbares, ibuprofen enthaltendes arzneimittel | |
| DE2611725A1 (de) | Zinksulfadiazin und dieses enthaltende dermatotherapeutische mittel zur behandlung von verbrennungen | |
| CH653892A5 (de) | Wundheilmittel zur bedeckung von wunden und verbrennungen. | |
| DE60204620T2 (de) | Nasenspray enthaltend Ondansetronhydrochlorid | |
| WO1988007364A1 (fr) | Onguent medicinal, son procede de production, formes d'application utilisant cet onguent et sa production | |
| DE69024053T2 (de) | Behandlung zur ermässigung von ödem und muskelschäden. | |
| EP1443944A1 (de) | Pharmazeutische anwendungen von hyaluronsäure-präparaten | |
| CA2283314C (en) | Ointment for the treatment of burns and of other skin diseases | |
| DE69727154T2 (de) | Land- und meeressschildkrötenöle, diese enthaltende zusammensetzungen, verfahren zu deren herstellung und verwendungen | |
| EP1196159A1 (de) | Verwendung von tosylchloramid(en) zur behandlung von erkrankungen der haut, der schleimhaut, von organen und geweben | |
| HK1045813B (zh) | 局部敷用的含甘油及斗篷草精華的非固體合成劑 | |
| JPS5913716A (ja) | 外用組成物 | |
| DE4300969C2 (de) | Verwendung von Malotilat zum Beschleunigen der Wundheilung bei Hautverbrennungen | |
| EP0450123A1 (de) | Diclofenac-Natrium enthaltende pharmazeutische Zusammensetzung zur topischen Anwendung | |
| DE2047049C3 (de) | Calciumsalz der 6-(N-Acetylamino)hexansSure, Verfahren zu seiner Herstellung und Arzneimittel mit einem Gehalt an diesem Salz | |
| DE10360425A1 (de) | Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung | |
| EP0442063B1 (de) | Verwendung von 2',4',6'-Trimethoxy-4-(1-pyrrolidinyl)butyrophenon zur lokalen Behandlung von trophischen Erkrankungen | |
| EP0484581B1 (de) | Verwendung von Thromboxan-A2-Antagonisten zur Verhinderung von degenerativen Vorgängen im penilen Gewebe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |